CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

The Year in Cardiovascular Medicine 2020: Coronary Intervention Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials The year in cardiovascular medicine 2020: interventional cardiology Coronary Angiography after Cardiac Arrest without ST-Segment Elevation Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention
|<<... 16 17 18 19 20 21 22 ...>>|

Review Article2016 Jul 25;9(14):1419-34.

JOURNAL：JACC Cardiovasc Interv. Article Link

Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials

Ferrante G, Rao SV, Valgimigli M et al. Keywords: bleeding; femoral access; percutaneous coronary intervention; radial access; vascular complications

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top